GO
Loading...

Enter multiple symbols separated by commas

Sanofi SA

More

  • BASEL, Switzerland, June 29- Drugmakers said on Monday they would continue to ship medicines to Greece in coming weeks, despite mounting unpaid bills, but warned supplies could be in jeopardy if Europe did not take emergency action. A copy of the letter to EU Health Commissioner Vytenis Andriukaitis from Richard Bergstrom, director general of the European...

  • June 26- Drug developer Celladon Corp said on Friday it may liquidate itself if it were unable to find a buyer, and was suspending development of its gene therapy for heart failure. Celladon said if it were to liquidate during the third quarter ending September, the net cash available for distribution to shareholders would be about $25 million- $30 million.

  • New drug compound may beat malaria with single $1 dose Wednesday, 17 Jun 2015 | 1:00 PM ET

    LONDON, June 17- Scientists have discovered a new anti-malarial compound that could treat patients with a single $1 dose, including those with strains of the mosquito-borne disease that are resistant to current drugs. In a vote of confidence for the project, German drugmaker Merck KgAA has secured the right to develop and commercialize the compound, assuming...

  • The Swiss drugmaker, which has licensed rights to dalcetrapib to Quebec- based DalCor Pharmaceuticals, said on Tuesday it would provide a companion diagnostic for use in the Phase III study. DalCor estimates about $250 million will be needed for the project, which will be run in collaboration with the Montreal Heart Institute and will screen more than 30,000...

  • June 7- Novo Nordisk's IDegLira combination drug for type 2 diabetes led to significant reductions in blood sugar, weight and rate of hypoglycemia compared with Sanofi's top-selling Lantus insulin product, according to data from a late-stage trial presented at a medical meeting on Sunday. In the 26- week, 557- patient phase III study presented at the ADA...

  • June 6- A long-acting insulin being developed by Eli Lilly and Co demonstrated greater blood sugar reduction than Sanofi SA's top-selling Lantus in patients with type 2 diabetes, according to data from three Phase III trials presented on Saturday. More patients in the studies who received Lilly's basal insulin peglispro also got their blood sugar down to the...

  • *Wall St banks say September rate hike more likely. Wall Street's top banks said they expect the Fed to begin raising interest rates in September, followed by another increase before the end of the year, according to a Reuters poll. "The market is excited about stronger jobs and higher wages, but before can pop the cork of the champagne bottle, they start thinking...

  • WASHINGTON, June 5- An experimental drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday before a meeting on Tuesday of a panel of outside advisers to the FDA who will discuss...

  • WASHINGTON, June 5- A drug made by Sanofi SA and Regeneron Pharmaceuticals Inc effectively lowers bad LDL cholesterol and is generally well tolerated, according to a preliminary review by the U.S. Food and Drug Administration. The review was published on Friday on the FDA's website before a meeting Tuesday of a panel of outside advisers who will discuss the drug...

  • Linking cancer drug prices to their performance Wednesday, 27 May 2015 | 1:54 PM ET

    Express Scripts is looking at the possibility of paying more for drugs that have been proven to show more benefit, and less where the drug hasn't.

  • Assuming approval from the U.S. Food and Drug Administration, Amgen Inc. will offer its drug, Repatha, as a biweekly 140 mg injection or a monthly injection of 420 mg, while Praluent, from Regeneron Pharmaceuticals Inc and Sanofi, will be offered in biweekly injections of 75 mg or 150 mg. Regeneron and Sanofi could enjoy a significant pricing advantage with their...

  • CHICAGO/ NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps- importing eggs from overseas or looking to egg alternatives. A spokeswoman for Archer Daniels Midland Co said that as egg supplies tighten and prices rise, the food processing...

  • CHICAGO and NEW YORK, May 22- As a virulent avian influenza outbreak continues to spread across the Midwestern United States, some egg-dependent companies are contemplating drastic steps: importing eggs from overseas or looking to egg alternatives. "Canada is short on eggs and has been buying heavily from the U.S. for the last several years," said Rick Brown, a...

  • LONDON, May 19- Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi. Recommendations for marketing approval by its Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

  • Regeneron Pharmaceuticals Inc, which signed a deal with Pennsylvania's Geisinger Health System in January 2014 to sequence partial genomes of some 250,000 volunteers, is already claiming discoveries based on the new approach. Pfizer Inc, Roche Holding AG and Biogen Inc are working on similar projects that use DNA and patient health data to find new drug...

  • These biotech names are ripe for mergers: Analysts Sunday, 10 May 2015 | 11:00 AM ET
    Biotech pharmaceuticals

    The next takeout target in biotech? Here are three eligible candidates

  • Hedgie: This biotech stock is going to zero Thursday, 7 May 2015 | 12:49 PM ET
    Afrezza is a rapid-acting, inhaled insulin for the treatment of diabetes.

    The hedge fund manager who has already made a killing betting against biotech company MannKind now says the stock will soon be worthless.

  • May 7- Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye injection Eylea to grow at a faster rate than it had previously forecast. Sales of Eylea in the United States jumped 51 percent to $541 million in the first quarter ended March 31, helping the company's adjusted profit handily beat the average analyst estimate by 20 cents.

  • Regeneron profit rises as Eylea sales jump Thursday, 7 May 2015 | 6:39 AM ET

    May 5- Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea. The U.S. biotechnology company's net profit rose to $76 million, or 66 per share, in the first quarter ended March 31, from $68.3 million, or 61 cents per share, a year earlier. Revenue, including collaboration payments...

  • WASHINGTON, May 6- The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their first amendment right to free speech. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of...